首页> 外文期刊>STEM CELLS >Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium
【24h】

Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium

机译:基质细胞衍生因子1激活信号转导和转录3激活剂以及粘着斑激酶的激活是人间充质干细胞迁移对肿瘤细胞条件培养基的反应所必需的

获取原文
获取原文并翻译 | 示例
       

摘要

Mesenchymal stem cells (MSCs) migrate to tumors both in vitro and in vivo. Gene expression profiling analysis reveals that stromal cell-derived factor 1 (SDF-1) is significantly upregulated in MSCs exposed to tumor cell-conditioned medium, when compared with cells treated with control medium, suggesting that SDF-1 signaling is important in mediating MSC migration. This study investigates downstream signaling during MSC migration in response to tumor cell-conditioned medium and recombinant SDF-1 protein treatments. We observed that both recombinant SDF-1 and tumor cell-conditioned medium were able to activate downstream signaling via signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) as revealed by increased phosphorylation of STAT3 and ERK1/2 in human MSCs (hMSCs). Significant impairment of in vitro migration was observed in the presence of MAPK/ERK kinase (MEK) inhibitor PD98059, whereas two Janus kinase 2 (Jak2) inhibitors completely abolished migration induced by tumor cell-conditioned medium. Impaired MSC migration correlated with decreased levels of phosphorylated STAT3 and ERK1/2, suggesting that SDF-1 stimulation activates Jak2/STAT3 as well as MEK/ERK1/2 signaling, which in turn promotes migration of MSCs toward tumor cells. Furthermore, stimulation of hMSCs with recombinant SDF-1 and tumor cell-conditioned medium also significantly activated the focal adhesion kinases (FAKs) and paxillin, which correlated with reorganization of F-actin filaments in hMSCs. Decreased phosphorylation of FAK and paxillin as well as disruption of cytoskeleton organization was observed following Jak2 and MEK inhibitor treatment. Taken together, our results provide insight into the molecular pathways responsible for MSC migration toward the tumor microenvironment and may provide the molecular basis for modifying MSCs for therapeutic purposes. STEM CELLS 2009;27:857-865
机译:间充质干细胞(MSCs)在体外和体内均迁移至肿瘤。基因表达谱分析显示,与用对照培养基处理的细胞相比,暴露于肿瘤细胞条件培养基的MSC中基质细胞衍生因子1(SDF-1)明显上调,这表明SDF-1信号在介导MSC中很重要移民。这项研究调查了响应肿瘤细胞条件培养基和重组SDF-1蛋白治疗的MSC迁移过程中的下游信号传导。我们观察到重组SDF-1和肿瘤细胞条件培养基均能够通过信号转导和转录激活因子3(STAT3)和细胞外信号调节激酶(ERK)丝裂原活化蛋白激酶(MAPK)激活下游信号传导通过增加人类MSC(hMSCs)中STAT3和ERK1 / 2的磷酸化。在存在MAPK / ERK激酶(MEK)抑制剂PD98059的情况下,观察到体外迁移的显着损害,而两种Janus激酶2(Jak2)抑制剂则完全消除了肿瘤细胞条件培养基诱导的迁移。受损的MSC迁移与磷酸化的STAT3和ERK1 / 2的水平降低相关,表明SDF-1刺激激活Jak2 / STAT3以及MEK / ERK1 / 2信号传导,进而促进MSC向肿瘤细胞的迁移。此外,用重组SDF-1和肿瘤细胞条件培养基刺激hMSC还显着激活了黏着斑激酶(FAK)和paxillin,这与hMSC中F-肌动蛋白丝的重组有关。在Jak2和MEK抑制剂处理后,观察到FAK和paxillin的磷酸化降低以及细胞骨架组织的破坏。综上所述,我们的结果提供了深入了解负责MSC向肿瘤微环境迁移的分子途径的信息,并可能为出于治疗目的修饰MSC提供分子基础。干细胞2009; 27:857-865

著录项

  • 来源
    《STEM CELLS》 |2009年第4期|857-865|共9页
  • 作者单位

    Department of Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA|Department of Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA;

    Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA;

    Department of Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA|Department of Pediatrics, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA;

    Department of Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA|Department of Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 14:13:18

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号